Search the Newsreel

BABCOCK & WILCOX ENTERPRISES Q2 2026 Earnings Preview: Recent $BW Insider Trading, Hedge Fund Activity, and More

Banco ABC Brasil (ABCB4): resultado do 2T26, diversificação e perspectivas

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Abcellera Biologics earnings missed, revenue fell short of estimates

Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance

This article first appeared on GuruFocus. Revenue: $84.8 billion, up 5% year-over-year. Adjusted Gross Profit: $3.5 billion, up 23%; gross profit margin expanded by 61 basis points to 4.16%. Adjusted Operating Expenses: $2.3 billion, up 27%, reflecting the OneOncology acquisition. Adjusted Operating Income: $1.2 …

Cencora (COR) Expands Credit Facilities And Resets Receivables Terms

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cencora (NYSE:COR) has amended its credit and receivables facilities, including changes to its multi currency revolving credit facility and receivables securitization arrangements. The company has …

AbCellera earnings on deck: Revenue dips as biotech eyes menopause trial

AbCellera Biologics Inc. is preparing to report its second-quarter results, with analysts forecasting a revenue decline despite recent partnership announcements. The company's cash management and the upcoming Phase 2 data readout for its lead menopause drug candidate, ABCL635, are key investor watch points. This …

Cencora raises full-year guidance after stronger-than-expected third-quarter results

Pack of pills ©jarmoluk Cencora (NYSE:COR) reported third-quarter results that exceeded Wall Street expectations, prompting the pharmaceutical services company to raise its full-year earnings guidance. The stronger performance helped lift the shares more than 3% in pre-market trading. For the quarter ended 30 June, …

Cencora (COR) Surpasses Q3 Earnings Estimates

Cencora (COR) came out with quarterly earnings of $4.48 per share, beating the Zacks Consensus Estimate of $4.37 per share. This compares to earnings of $4 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Cencora’s (NYSE:COR) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

Cencora's (NYSE:COR) Q2 CY2026 Earnings Results: Revenue In Line With Expectations Healthcare distributor Cencora (NYSE:COR) met Wall Street's revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAAP profit of $4.48 per share was 3% above analysts' …

Cencora Reports Fiscal 2026 Third Quarter Results

Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted Diluted EPS Guidance Range Raised to $17.75 to $17.95 for Fiscal 2026 Cencora Repurchased $1 Billion of …

Babcock International Group (LSE:BAB) Stock Sees Modest Fair Value Cut After Mixed Analyst Changes

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest analyst updates for Babcock International Group centre on price targets that now span roughly £11.00 to £15.56 per share, compared with …

Cencora hebt Prognose an und übertrifft Erwartungen – Aktie legt zu

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview

Abcellera Biologics Inc (ABCL) is projected to report a loss of 14 cents per share. This earnings preview is based on Refinitiv data and was published by Reuters.

Babcock & Wilcox stock may move 17% on earnings release

AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?

AbCellera Biologics (ABCL) has signed a new collaboration with Vertex Pharmaceuticals for autoimmune disease treatments. Despite a recent share price rebound, the stock remains undervalued according to Simply Wall St's narrative, suggesting a fair value of $10.43 compared to its last close of $5.71. …

Cencora (COR) Remains Attractive Despite Temporary Headwinds

Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the "Carillon Eagle Mid Cap Growth Fund". A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% …

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $4.37 per share in its upcoming report, which indicates a year-over-year increase of 9.3%. Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter. Over the last 30 days, there …

AbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement

AbCellera Biologics (ABCL) recently announced a collaboration with Vertex Pharmaceuticals for T-cell engagers, receiving $28 million upfront and potential milestones. This deal, along with a previous one with Jazz Pharmaceuticals, validates AbCellera's technology and provides non-dilutive cash, though the company still faces risks from …

Abcellera Biologics Inc (ABCL) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Abcellera Biologics Inc (ABCL), ranking it 232 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.64. The company's financial status is weak with low operating efficiency, despite a significant year-over-year …

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

ABCL Looks 3.8% Overvalued on GF Value™

AbCellera Biologics Inc (ABCL) is indicated as 3.8% overvalued according to GuruFocus's GF Value™, though its Price-to-Sales ratio is only slightly above historical median. The company, a clinical-stage biotechnology firm, recently partnered with Vertex Pharmaceuticals, receiving a $28 million upfront payment to co-develop multispecific …

Abcellera Biologics Inc (ABCL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Abcellera Biologics Inc (ABCL), highlighting its beta value of 1.12, indicating higher volatility compared to the S&P 500. The company's risk assessment score is 4.09, ranking it 102 out of 384 in the Biotechnology & Medical Research …

Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and …

AbCellera Biologics Number of Employees 2026 | Employee Count & Headcount Data

AbCellera Biologics (NASDAQ: ABCL) had approximately 561 employees worldwide as of March 2026, marking a 5.9% decline since 2023. Despite this decrease in headcount, the company is actively hiring, with 56 job postings in 2026, a 54.5% increase from the previous year. The workforce …

Good Neighbor Pharmacy® Named #1 in Customer Satisfaction with Chain Drug Store Pharmacies and Most Trusted by JD Power

Recognition coincides with ThoughtSpot, Cencora's flagship annual tradeshow and conference for community care providers CONSHOHOCKEN, Pa., July 29, 2026--(BUSINESS WIRE)--Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, has been ranked "#1 in Customer Satisfaction with Chain Drug Store Pharmacies" in …

AbCellera expands multispecific T-cell engager licensing with USD 28m Vertex deal for autoimmune disease

AbCellera Biologics has partnered with Vertex Pharmaceuticals in a deal worth $28 million upfront to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery while Vertex retains development and commercialization rights, with AbCellera eligible for milestone payments and royalties. …